At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
eltrombopag 12.5 milligrams (mg) tablet +1 moredrug
Likely dose
eltrombopag 12.5 milligrams (mg) tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TPL111913, a Multi-centre, Open Label, Dose Ranging Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
In Brief
A Phase 2 clinical trial evaluating eltrombopag 12.5 milligrams (mg) tablet and eltrombopag 25 mg tablet for Liver Diseases. Completed, enrolled 38 participants across 10 sites.
Detailed Summary
This is an open label, multi-centre, dose ranging study to assess efficacy, safety and pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Diseases
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedMar 2009
Primary CompletionAug 2009
TodayJul 2026
First PostedMar 13, 2009
Enrollment StartJan 1, 2009
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.3 years ago
Interventions
eltrombopag 12.5 milligrams (mg) tabletdrug
eltrombopag 12.5 mg tablet once a day
eltrombopag 25 mg tabletdrug
eltrombopag 25 mg tablet once a day